Prevalence, tumorigenic role, and biochemical implications of rare BRAF alterations

Thyroid

Volumn 24, Issue 5, 2014, Pages 809-819

  Barollo, Susi ^a   Pezzani, Raffaele ^a   Cristiani, Andrea ^a,b   Redaelli, Marco ^a   Zambonin, Laura ^a   Rubin, Beatrice ^a   Bertazza, Loris ^a   Zane, Mariangela ^a   Mucignat Caretta, Carla ^a   Bulfone, Alessandro ^b   Pennelli, Gianmaria ^a   Casal Ide, Eric ^a   Pelizzo, Maria Rosa ^a   Mantero, Franco ^a   Moro, Stefano ^a   Mian, Caterina ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b CENTER FOR ADVANCED STUDIES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; BRAF PROTEIN, HUMAN; CODON;

ADULT; AGED; ARTICLE; BRAF GENE; COMPUTER MODEL; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; EXON; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; FOLLOW UP; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR DYNAMICS; NUCLEOTIDE SEQUENCE; ONCOGENE; POINT MUTATION; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; WESTERN BLOTTING; WILD TYPE; ADENOCARCINOMA; CARCINOMA; CHEMICAL STRUCTURE; CHEMISTRY; CODON; COHORT ANALYSIS; ENZYME ACTIVE SITE; GENETIC ASSOCIATION; GENETICS; METABOLISM; MUTATION; PROTEIN CONFORMATION; PROTEIN STABILITY; THYROID TUMOR; YOUNG ADULT;

ADENOCARCINOMA, FOLLICULAR; ADULT; AGED; CARCINOMA; CATALYTIC DOMAIN; CODON; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MIDDLE AGED; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; MUTATION; PROTEIN CONFORMATION; PROTEIN STABILITY; PROTO-ONCOGENE PROTEINS B-RAF; THYROID CARCINOMA, ANAPLASTIC; THYROID NEOPLASMS; YOUNG ADULT;

EID: 84901284833     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2013.0403     Document Type: Article

References (39)

1. Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK 2003 Cancer survival and incidence from the surveillance, epidemiology, and end results (SEER) program. Oncologist 8:541-552. (Pubitemid 37467370)
2. Xing M 2007 BRAF mutation in papillary thyroid cancer: Pathogenic role, molecular bases, and clinical implications. Endocr Rev 28:742-762. (Pubitemid 350294294)
3. Kimura ET, Nikiforova MN, Zhu ZW, Knauf JA, Nikiforov YE, Fagin JA 2003 High prevalence of BRAF mutations in thyroid cancer: Genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454-1457. (Pubitemid 36373628)
4. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE 2003 BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399-5404. (Pubitemid 37452745)
5. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW, Sidransky D 2003 BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95:625-627. (Pubitemid 36553510)
6. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA 2002 Mutations of the BRAF gene in human cancer. Nature 417:949-954. (Pubitemid 34716871)
7. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R 2004 Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855-867. (Pubitemid 38410730)
8. Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A, Tosi E, Cavaliere A, Gulino A, Filetti S, Russo D 2007 BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab 92:2840-2843. (Pubitemid 47037399)
9. Riesco-Eizaguirre G, Gutierrez-Martinez P, Garcia-Cabezas MA, Nistal M, Santisteban P 2006 The oncogene BRAFV600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na + /I-Targeting to the membrane. Endocr Relat Cancer 13:257-269.
10. Trovisco V, Vieira de Castro I, Soares P, Máximo V, Silva P, Magalhäes J, Abrosimov A, Guiu XM, Sobrinho-Simöes M 2004 BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol 202:247-251. (Pubitemid 38208663)
11. Oler G, Ebina KN, Michaluart P, Kimura ET, Cerutti J 2005 Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis reveals a new mutation in metastasis. Clin Endocrinol 62:509-511.
12. Moretti S, Macchiarulo A, De Falco V, Avenia N, Barbi F, Carta C, Cavaliere A, Melillo RM, Passeri L, Santeusanio F, Tartaglia M, Santoro M, Puxeddu E 2006 Biochemical and molecular characterization of the novel BRAF (V599ins) mutation detected in a classic papillary thyroid carcinoma. Oncogene 25:4235-4240. (Pubitemid 44079457)
13. Pennelli G, Vianello F, Barollo S, Pezzani R, Merante Boschin I, Pelizzo MR, Mantero F, Rugge M, Mian C 2011 BRAF(K601E) mutation in a patient with a follicular thyroid carcinoma. Thyroid 21:1393-1396.
14. Brzezianska E, Pastuszak-Lewandoska D 2011A minireview: The role of MAPK/ERK and PI3K/Akt pathways in thyroid follicular cell-derived neoplasm. Front Biosci 16:422-439.
15. Fratev FF, Jonsdottir SO 2009 An in silico study of the molecular basis of B-RAF activation and conformational stability. BMC Struct Biol 9:47.
16. Fratev F, Jonsdottir SO 2010 The phosphorylation specificity of B-RAF(WT), B-RAF(D594V), B-RAF(V600E) and B-RAF(K601E) kinases: An in silico study. J Mol Graph 28:598-603.
17. Pelizzo MR, Boschin IM, Barollo S, Pennelli G, Toniato A, Zambonin L, Vianello F, Piotto A, Ide EC, Pagetta C, Sorgato N, Torresan F, Girelli ME, Nacamulli D, Mantero F, Mian C 2011 BRAF analysis by fine needle aspiration biopsy of thyroid nodules improves preoperative identification of papillary thyroid carcinoma and represents a prognostic factor. A mono-institutional experience. Clin Chem Lab Med 49:325-329.
18. Barollo S, Pennelli G, Vianello F, Watutantrige Fernando S, Negro I, Merante Boschin I, Pelizzo MR, Rugge M, Mantero F, Nacamulli D, Girelli ME, Busnardo B, Mian C 2010 BRAF in primary and recurrent papillary thyroid cancers: The relationship with I-131 and 2-[F-18]fluoro-2-deoxy-Dglucose uptake ability. Eur J Endocrinol 163:659-663.
19. Mariniello B, Rosato A, Zuccolotto G, Rubin B, Cicala MV, Finco I, Iacobone M, Frigo AC, Fassina A, Pezzani R, Mantero F 2012 Combination of sorafenib and everolimus impacts therapeutically on adrenocortical tumor models. Endocr Relat Cancer 19:527-539.
20. Redaelli M, Franceschi V, Capocefalo A, D'Avella D, Denaro L, Cavirani S, Mucignat-Caretta C, Donofrio G 2012 Herpes simplex virus type 1 thymidine kinase-Armed bovine herpesvirus type 4-based vector displays enhanced oncolytic properties in immunocompetent orthotopic syngenic mouse and rat glioma models. Neuro Oncol 14:288-301.
21. Rose PW, Beran B, Bi C, Bluhm WF, Dimitropoulos D, Goodsell DS, Prlic A, Quesada M, Quinn GB, Westbrook JD, Young J, Yukich B, Zardecki C, Berman HM, Bourne PE 2011 The RCSB Protein Data Bank: Redesigned web site and web services. Nucleic Acids Res 39:D392-D401.
22. Stephens R, Sithanandam G, Copeland T, Kaplan D, Rapp U, Morrison D 1992 95-Kilodalton B-Raf serine threonine kinase-identification of the protein and its major autophosphorylation site. Mol Cell Biol 12:3733-3742.
23. MOE: Molecular Operating Environment. www.chemcomp .com
24. Arnold K, Bordoli L, Kopp J, Schwede T 2006 The SWISS-MODEL workspace: A web-based environment for protein structure homology modelling. Bioinformatics 22: 195-201.
25. Case DA, Cheatham TE 3rd, Darden T, Gohlke H, Luo R, Merz KM Jr, Onufriev A, Simmerling C, Wang B, Woods RJ 2005 The Amber biomolecular simulation programs. J Comput Chem 26:1668-1688. (Pubitemid 43076180)
26. Labute P 2009 Protonate3D: Assignment of ionization states and hydrogen coordinates to macromolecular structures. Proteins 75:187-205.
27. Cristiani A, Brisotto N, Cedrati FC, Floris M, Scapozza L, Moro S 2011 ClickMD: An intuitive web-oriented molecular dynamics platform. Future Med Chem 3:923-931.
28. Harvey MJ, Giupponi G, De Fabritiis G 2009 ACEMD: Accelerating biomolecular dynamics in the microsecond time scale. J Chem Theory Comput 5:1632-1639.
29. Humphrey W, Dalke A, Schulten K 1996 VMD: Visual molecular dynamics. J Mol Graph 14:33-38. (Pubitemid 26152973)
30. RMSD Trajectory Tools. http://physiology.med.cornell.edu/ faculty/hweinstein/vmdplugins/rmsdtt
31. Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, Ma'ximo V, Botelho T, Moreira S, Meireles AM, Magalha ?es J, Abrosimov A, Cameselle-Teijeiro J, Sobrinho-Simöes M 2005 Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch 446:589-595.
32. Gauchotte G, Philippe C, Lacomme S, Léotard B, Wissler MP, Allou L, Toussaint B, Klein M, Vignaud JM, Bressenot A 2011 BRAF, p53 and SOX2 in anaplastic thyroid carcinoma: Evidence for multistep carcinogenesis. Pathology 43:447-452.
33. Eisenhardt AE, Olbrich H, Röring M, Janzarik W, Anh TN, Cin H, Remke M, Witt H, Korshunov A, Pfister SM, Omran H, Brummer T 2011 Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma. Int J Cancer 129:2297-2303.
34. Trovisco V, Soares P, Soares R, Magalhaes J, Sa-Couto P, Sobrinho-Simoes M 2005A new BRAF gene mutation detected in a case of a solid variant of papillary thyroid carcinoma. Hum Pathol 36:694-697. (Pubitemid 40922577)
35. Hou P, Liu D, Xing M 2007 Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer. Cell Cycle 6:377-379.
36. Lupi C, Giannini R, Ugolini C, Proietti A, Berti P, Minuto M, Materazzi G, Elisei R, Santoro M, Miccoli P, Basolo F 2007 Extensive clinical experience-Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 92:4085-4090. (Pubitemid 350074715)
37. Asioli S, Erickson LA, Righi A, Lloyd RV 2013 Papillary thyroid carcinoma with hobnail features: Histopathologic criteria to predict aggressive behavior. Hum Pathol 44:320-328.
38. Zhang BH, Guan KL 2000 Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. EMBO J 19:5429-5439.
39. Cruz F 3rd, Rubin BP, Wilson D, Town A, Schroeder A, Haley A, Bainbridge T, Heinrich MC, Corless CL 2003 Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res 63:5761-5766. (Pubitemid 37187472)